Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
Top Page
Thyrocare Technologies Ltd
(THYROCARE)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹425.00
▼(-7.43% Downside)
Action:DowngradedDate:12/03/25
Thyrocare Technologies Ltd shows strong financial performance with robust revenue growth and efficient cash flow management, which are the primary drivers of the stock score. Technical analysis indicates a positive trend, though valuation metrics suggest the stock is priced at a premium. The absence of earnings call data and notable corporate events limits additional insights.
Positive Factors
Revenue Growth
Sustained ~21% revenue growth indicates expanding test volumes and stronger market penetration. Over a 2–6 month horizon this supports scale benefits for centralized labs, underpins pricing leverage on test bundles, and provides a durable top-line base for reinvestment and margin recovery.
Negative Factors
Margin Pressure
A declining net margin suggests rising operating costs or higher financial charges that could persist. If structural cost inflation or pricing pressure continues, margins may compress, reducing free cash flow and curtailing the firm's ability to invest or return capital without efficiency gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~21% revenue growth indicates expanding test volumes and stronger market penetration. Over a 2–6 month horizon this supports scale benefits for centralized labs, underpins pricing leverage on test bundles, and provides a durable top-line base for reinvestment and margin recovery.
Read all positive factors
Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹63.75B
Dividend Yield0.68%
Average Volume (3M)56.30K
Price to Earnings (P/E)61.2
Beta (1Y)0.55
Revenue Growth21.06%
EPS Growth56.75%
CountryIN
Employees1,693
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)24.16
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.35
Price to Sales (P/S)1.87
P/FCF Ratio8.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.1
Revenue Forecast (FY)₹9.48B
Thyrocare Technologies Ltd Business Overview & Revenue Model
Company Description
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical d...
How the Company Makes Money
Thyrocare makes money by providing diagnostic testing services and collecting fees for processing patient samples in its laboratories. Its core revenue stream comes from pathology lab test volumes (including individual tests and bundled wellness/p...
Thyrocare Technologies Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.63B | 6.87B | 5.72B | 5.27B | 5.89B | 4.95B |
| Gross Profit | 5.90B | 4.96B | 1.81B | 3.63B | 4.19B | 3.31B |
| EBITDA | 2.45B | 2.04B | 1.48B | 1.31B | 2.64B | 1.84B |
| Net Income | 1.28B | 915.10M | 707.60M | 644.90M | 1.76B | 1.13B |
Balance Sheet | ||||||
| Total Assets | 6.80B | 6.93B | 6.44B | 6.33B | 6.08B | 5.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 1.92B | 1.77B | 1.51B | 1.39B | 1.18B |
| Total Debt | 246.80M | 246.80M | 423.40M | 233.10M | 207.00M | 84.90M |
| Total Liabilities | 1.46B | 1.46B | 1.16B | 975.00M | 810.90M | 1.19B |
| Stockholders Equity | 5.34B | 5.47B | 5.27B | 5.34B | 5.27B | 4.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.11B | 1.46B | 1.06B | 856.60M | 755.80M | 877.70M |
| Operating Cash Flow | 1.27B | 1.91B | 1.68B | 1.29B | 1.13B | 1.16B |
| Investing Cash Flow | 47.10M | -525.20M | -912.80M | -389.90M | -235.70M | -502.30M |
| Financing Cash Flow | -1.18B | -1.30B | -848.00M | -861.80M | -894.10M | -615.70M |
Thyrocare Technologies Ltd Technical Analysis
Neutral
459.10
Price Trends
385.79
Positive
421.52
Negative
418.25
Negative
Market Momentum
3.14
Negative
53.70
Neutral
67.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Neutral. The current price of 459.1 is above the 20-day moving average (MA) of 375.49, above the 50-day MA of 385.79, and above the 200-day MA of 418.25, indicating a neutral trend. The MACD of 3.14 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 67.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:THYROCARE.
Thyrocare Technologies Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹115.77B | 63.11 | ― | 0.20% | 15.79% | 12.14% | |
69 Neutral | ₹63.75B | 61.22 | ― | 0.68% | 21.06% | 56.75% | |
61 Neutral | ₹98.84B | 60.35 | ― | 0.21% | 18.95% | 9.30% | |
58 Neutral | ₹19.10B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
57 Neutral | ₹22.69B | 20.54 | ― | 0.49% | 1.02% | -24.31% | |
54 Neutral | ₹25.78B | 205.09 | ― | 0.92% | 21.45% | -41.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:THYROCARE
Thyrocare Technologies Ltd
400.55
102.93
34.58%
IN:KRSNAA
Krsnaa Diagnostics Limited
588.65
-129.89
-18.08%
IN:MEDIASSIST
Medi Assist Healthcare Services Limited
345.15
-94.75
-21.54%
IN:METROPOLIS
Metropolis Healthcare Ltd.
476.75
52.35
12.34%
IN:MOREPENLAB
Morepen Laboratories Limited
41.41
-19.36
-31.86%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,126.95
111.25
10.95%
Thyrocare Technologies Ltd Corporate Events
Thyrocare Receives ₹2.03 Crore Tax Demand, Plans to Contest
Mar 29, 2026
Thyrocare Technologies has disclosed that it received a notice of demand from the Income Tax Department’s Assessment Unit under Section 156 of the Income-tax Act for Assessment Year 2024-25, raising a tax demand of ₹2,02,82,260. The co...
Thyrocare boosts Tanzania subsidiary with fresh capital infusion
Feb 24, 2026
Thyrocare Technologies Ltd has infused an additional USD 475,000, equivalent to about INR 4.33 crore, into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Ltd, by subscribing to compulsorily convertible irredeemable preference shares. ...
Thyrocare Wins Dual Honours at National Diagnostics Forum 2026
Jan 22, 2026
Thyrocare Technologies Limited announced that it has received two major recognitions at the 4th Edition of the National Diagnostics Forum Awards 2026, organized by Voice of Healthcare in Mumbai. The company was named “Best Diagnostic Lab Ch...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.